FundamentalsNews digest Peer analysis
Earnings report Q4 2023

XRAY Sees Slight Increase in Revenue Amid Segment Realignment

Segments of Revenue

XRAY's revenue primarily comes from the sale of dental equipment and healthcare consumables. The company's revenue is divided into four reportable segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. In the latest year, Connected Technology Solutions generated $1.22 billion, Essential Dental Solutions brought in $1.43 billion, Orthodontic and Implant Solutions made $1.01 billion, and Wellspect Healthcare contributed $270 million. The total net sales for the year were $3.92 billion, a slight increase from the previous year's $3.92 billion.


The company's strength lies in its diverse product portfolio, which includes equipment and instruments, CAD/CAM, orthodontics, implants and prosthetics. The Essential Dental Solutions segment saw a slight increase in revenue, indicating a steady demand for these products. The company's stock repurchase program, with an authorization to repurchase $1.44 billion in shares, also demonstrates a strong financial position.


Despite the slight increase in total net sales, some segments experienced a decrease in revenue. The Connected Technology Solutions segment saw a decrease from $1.35 billion to $1.22 billion, and the Orthodontic and Implant Solutions segment also saw a slight decrease.


The company underwent a significant organizational change, realigning its reporting structure. This resulted in a change in the reportable segments, which may have impacted the revenue distribution among the segments.


XRAY experienced a slight increase in total net sales in the latest year, with revenue primarily driven by the Essential Dental Solutions segment. Despite some segments experiencing a decrease in revenue, the company's diverse product portfolio and strong stock repurchase program indicate a solid financial position. However, the recent organizational changes and segment realignment may pose challenges moving forward.

Source documents

Form 10-K  filed on Feb 29, 2024
127 pages scanned

Reference data

Company financials Q4 revenue 953M
Analyst estimates Q4 EPS missed by -3.48%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.